Phase 1 Clinical Study of JTE-451 ointment -Single and Multiple Dose Study-

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080225252

Enrollment

Registered

2020-06-30

Start date

2020-07-06

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Plaque psoriasis

Interventions

investigational material(s) Generic name etc : JTE-451A INN of investigational material : - Therapeutic category code : 269 Other agents for epidermis Dosage and Administration for Investigational mat

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Cohort 1 -BMI of 18.5 to 25.0 Cohort 2,Cohort 3 -Subjects with a diagnosis of plaque psoriasis for at least 1 year -Have a mPASI score of 4.5 or greater

Exclusion criteria

Exclusion criteria: Cohort 1 -Presence of skin conditions that would interfere with study evaluation Cohort 2, Cohort 3 -Presence of pustular psoriasis, guttate psoriasis, erythrodermic psoriasis or medication-induced psoriasis -Presence of infections

Design outcomes

Primary

Measure	Time frame
safety Safety	—

Secondary

Measure	Time frame
pharmacokinetics Pharmacokinetics	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026